Research & Development
Yarrow Bioscience completes VYNE merger and begins Phase 2 trial of YB-101
27 July 2026 - Clinical-stage biotechnology company Yarrow Bioscience Inc (Nasdaq:YARW) announced on Monday that it has completed its merger with VYNE Therapeutics Inc and closed previously announced ...
NewAmsterdam Pharma and Menarini Group report positive CHMP opinion for obicetrapib monotherapy and obicetrapib/ezetimibe combination
27 July 2026 - Late-stage biopharmaceutical company NewAmsterdam Pharma Company N.V. (Nasdaq:NAMS) and its partner Menarini Group announced on Friday that the Committee for Medicinal Products for Huma...
Asymchem's DH2 site completes first FDA inspection for continuous manufacturing of API
27 July 2026 - Asymchem, a China-based global contract development and manufacturing organisation (CDMO), announced on Friday that its dedicated carbapenem active pharmaceutical ingredient (API) manuf...
Par Health launches generic version of Janumet XR tablets in US
27 July 2026 - US pharmaceutical company Par Health Inc announced on Friday the launch of its generic version of Merck's Janumet XR (sitagliptin and metformin HCl extended-release) tablets for or...
FDA approves Furoscix ReadyFlow for at-home treatment of edema
24 July 2026 - US biopharmaceutical company MannKind Corporation (NASDAQ: MNKD) announced on Friday that it has received US Food and Drug Administration approval for Furoscix ReadyFlow, a furosemide i...
CHMP backs Gilead's Trodelvy-Keytruda combination for first-line metastatic triple-negative breast cancer
24 July 2026 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recom...